Create your Personal Health Record and unlock support built around you

Aligned with your diagnosis, treatment and where you are in your care. It lets HealthTree show you:

Treatments and trials you qualify for
Education for your stage of care
Financial support for your medications
Solutions to your side effects

Learn more about HealthTree

Video

What is fedratinib (Inrebic)?

Posted by

HealthTree

• October 24, 2025

Description

Learn about what fedratinib is in myelofibrosis treatment through this video.

On this video

Andrew Srisuwananukorn, MD

Transcript

What is fedratinib?

Fedratinib is an additional JAK2 inhibitor. Ruxolitinib inhibits multiple proteins, including JAK1 and JAK2. Fedratinib, on the other hand, has been thought to inhibit more selectively JAK2.

In clinical practice, this is a very specific portion of patients that are likely to benefit from fedratinib specifically.

The JAKARTRA trial and the Freedom trials were looking at the clinical utility of fedratinib, particularly for patients that had a suboptimal response to frontline ruxolitinib. So patients that are typically using fedratinib are those reaching for this therapy in second line after the ruxolitinib therapies weren't working for them.

Related Content